Brought to you by 
Esperion licenses patents from Region Wallonne
06 Feb 2001
Executive Summary
Esperion Therapeutics (drugs to treat cardiovascular disease) has licensed exclusive worldwide rights to Region Wallonne's patents and knowledge of ProapolipoproteinA-I (ProApoA-I), the major HDL protein, to treat acute coronary diseases including unstable angina and ischemia.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Esperion licenses patents from Region Wallonne
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice